

HIV-1 protease-IN-7

Cat. No.:	HY-151250
CAS No.:	2916441-36-4
Molecular Formula:	C ₆₈ H ₁₀₄ N ₁₀ O ₁₂ S
Molecular Weight:	1285.68
Target:	HIV Protease
Pathway:	Anti-infection; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	HIV-1 protease-IN-7 (compound 16) is an orally active HIV-1 protease inhibitor (IC ₅₀ =3.52 nM, EC ₅₀ =37 nM) ^[1] .						
IC₅₀ & Target	HIV-1 protease ^[1] .						
In Vivo	HIV-1 protease-IN-7 (2.57 mg/kg; p.o.; single) exhibits good plasma total clearance and oral bioavailability ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.						
	Animal Model:	Male Sprague-Dawley rats (8-week-old) ^[1] .					
	Dosage:	2.57 mg/kg (2 μM/kg)					
	Administration:	Oral administration; single.					
	Result:	Pharmacokinetic Parameters of HIV-1 protease-IN-7 in male Sprague-Dawley rats ^[1] .					
		metabolic stability rat/human (%)	CL _{tot} (mL/min/kg)	Vd _{ss} (L/kg)	t _{1/2} (h)	F (%)	serum fu(%)
	PO (2.57 mg/kg)	63/23	8.2	1.9	3.9	3.3	0.1

REFERENCES

[1]. Kusumoto Y, et al. Highly Potent and Oral Macrocytic Peptides as a HIV-1 Protease Inhibitor: mRNA Display-Derived Hit-to-Lead Optimization. ACS Medicinal Chemistry Letters, 2022.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA